|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
|Ticker||Company||Price||Change||Chg %||Mkt Cap|
You can purchase shares of Gain Therapeutics (NASDAQ: GANX) through any online brokerage.
There are no as such competitors for Gain Therapeutics.
The latest price target for Gain Therapeutics (NASDAQ: GANX) was reported by Oppenheimer on April 12, 2021. The analyst firm set a price target for 30.00 expecting GANX to rise to within 12 months (a possible 223.97% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Gain Therapeutics (NASDAQ: GANX) is $9.26 last updated Thu Jun 17 2021 20:00:03 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Gain Therapeutics.
There is no upcoming split for Gain Therapeutics.
Gain Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.